Navigation Links
EU Drug Regulator Highlights Depression Danger of Weight-loss Pill

The European drug regulator EMEA said Thursday it had maintained authorisation of weight-loss pill Acomplia in the European Union, but had ordered it to be withheld from people suffering from depression.

A panel of experts from the US Food and Drug Administration concluded in June that the dieting treatment, which can also be used to treat diabetes, was unsafe because it caused suicidal thoughts as a side-effect.

The maker of the drug, French group Sanofi-Aventis, abandoned attempts to win approval for the drug in the United States as a result.

The European Medicines Agency (EMEA) recommended Thursday that Acomplia, also known as Rimonabant, should not be given to patients with depression or those taking anti-depressants because of the risk of psychiatric side-effects.

The agency said that depression was known as the main side-effect of the drug and this had been signalled at the time of its approval in June 2006.

However, the Agency's Committee for Medicinal Products for Human Use (CHMP) had recommended upgrading the warning about depression.

Sanofi-Aventis, the fourth-biggest drug maker in the world, announced afterwards that it had changed its labelling to take into account the EMEA's comments.

The recommendation from the EMEA will be sent to doctors prescribing drugs in the countries where the drug in being sold.


'"/>




Page: 1

Related medicine news :

1. US Regulator Sees No Link Between Tamiflu And Japan Deaths
2. Tumor Suppressor p53s Contradictory Regulatory System
3. A brush with the U.S. Regulators can cost a fortune
4. Cancer-causing Property Of Teflon Leaves US Regulators Concerned
5. Human Complexity Can Be Attributed To Regulatory Sequence
6. Regulators Object Drug Produced from Genetically Engineered Farm Animals
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
10. Drug Regulators Need To Think In Long-Term, Say Charities
11. Regulatory T-cells – Protector or Cause of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: